REGN · CIK 872589
What Regeneron Pharmaceuticals, Inc. told the SEC could break it.
Regeneron's register is dominated by concentration on both what it sells and who it sells through. A handful of products carry the company — EYLEA HD and EYLEA together were 31% of 2025 total revenue, alongside heavy reliance on Dupixent — while just two customers accounted for 77% of gross product revenue (and 87% of net trade receivables), an extreme distribution-channel and credit concentration. It also leans on partners and suppliers to bring products to market: collaborations with Sanofi and Bayer plus a chain of CROs, contract manufacturers and fill-finish providers, and China-based suppliers for certain raw materials and services — with the IRA's new 10% Part D manufacturer discount adding pricing pressure from 2025.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- product concentration — EYLEA HD/EYLEA (31% of total revenue) and Dupixent dependencehigh
Regeneron is substantially dependent on EYLEA HD and EYLEA (aggregate U.S. net product sales = 31% of total revenue in 2025, down from 42% in 2024, with increasing reliance on EYLEA HD) and on Dupixent; loss of exclusivity or competitive pressure on these key products could materially reduce revenue.
“We are substantially dependent on the success of EYLEA HD and EYLEA... For the years ended December 31, 2025 and 2024, our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% and 42% of our total revenues, respect[ively]”
SEC filing →As of 2026 - two customers = 77% combined of gross product revenue (Customer A 50%, Customer B 27%); 87% of net trade ARhigh
In 2025 two customers each exceeded 10% of Regeneron's total gross product revenue and together accounted for 77% (Customer A 50%, Customer B 27%), and two individual customers represented 87% of net trade accounts receivable — an extreme distribution-channel/credit concentration.
“On a combined basis, our product sales to these customers accounted for 77% of our total gross product revenue for the year ended December 31, 2025.”
Regulatory & policy
- China-based supplier/service-provider dependence (raw materials, preclinical/clinical) + IRA Part D manufacturer discountmedium
Regeneron (and its collaborators/third parties) depend on China-based suppliers/service providers for certain raw materials, products, services and preclinical/clinical programs, which restrictions could disrupt; separately, effective Jan 1, 2025 the IRA's new manufacturer-discount program requires Regeneron to give CMS a 10% discount on covered Part D drugs.
“the pharmaceutical industry generally, and in some instances our Company or our collaborators or other third parties on which we rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities.”
Supplier concentration
- dependence on Sanofi & Bayer collaborations for commercialization; CRO/CMO/fill-finish service providersmedium
Regeneron relies on its collaborations with Bayer and Sanofi to commercialize some marketed products and depends on third-party collaborators and service providers (CROs, outside testing labs, clinical-investigator sites, third-party manufacturers, fill/finish providers, packagers/labelers) that may fail to perform adequately in development, manufacture and commercialization.
“We depend upon third-party collaborators, including Sanofi and Bayer, and service providers such as CROs, outside testing laboratories, clinical investigator sites, third-party manufacturers, fill/finish providers, and product packagers and labelers, to assist us in the manufacture and preclinical and[ clinical development]”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Nex-z is the subject of a co-development and co-promotion (“Co/Co”) agreement (the “ATTR Co/Co”) with Regeneron, for which we are the clinical and commercial lead party and Regeneron is the participating party. Regeneron shares in approximately 25% of w”
Cited →Ultragenyx Pharmaceutical Inc.
“the drug substance and drug product for Crysvita and Evkeeza are made, respectively, by KKC pursuant to a license and collaboration agreement and supply agreements and Regeneron pursuant to a supply agreement.”
Cited →
Its suppliers
“We co-commercialize Dupixent in the United States and in certain countries outside the United States. We supply certain commercial bulk product to Sanofi. We and Sanofi equally share profits from sales within the United States, and share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55% (Sanofi)/45% (us).”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch